| アブストラクト | AIM: To investigate adherence to and persistence with free combination therapy (daily basal insulin plus an injectable glucagon-like peptide-1 receptor agonist [GLP-1 RA]) versus fixed-ratio combination (FRC) therapy (basal insulin plus a GLP-1 RA) among individuals with type 2 diabetes (T2D) in Japan. MATERIALS AND METHODS: This retrospective, observational cohort study used DeSC-IQVIA Integrated claims data from Japan to identify adults (aged >/= 18 years) with confirmed T2D and >/= 1 prescription for a GLP-1 RA (with predefined basal insulin persistence window) or an FRC during October 2019 to September 2023. Study index was date of first GLP-1 RA or FRC prescription; follow-up was 365 days. The primary objective was to evaluate adherence to and persistence with free combination therapy versus FRC therapy. RESULTS: Age (mean [standard deviation]) at index was statistically significantly higher in the free combination group (67.0 [13.85] years, n = 2063) than in the FRC group (65.7 [13.85] years, n = 2386) (p = 0.002). Odds of optimal adherence at end of follow-up were statistically significantly higher with FRC therapy than with free combination therapy (adjusted odds ratio [95% confidence interval]: 1.96 [1.73-2.23]; p < 0.001). Risk of discontinuation by end of follow-up was statistically significantly lower with FRC therapy than with free combination therapy (adjusted hazard ratio [95% confidence interval]: 0.66 [0.61-0.71]; p < 0.001). Adherence and persistence findings were similar in elderly individuals. CONCLUSIONS: In this real-world, adult population with T2D in Japan, FRC therapy was associated with improved adherence and persistence versus free combination therapy. |
|---|
| ジャーナル名 | Diabetes, obesity & metabolism |
|---|
| Pubmed追加日 | 2026/5/6 |
|---|
| 投稿者 | Miyatsuka, Takeshi; Brash, James; Davies, Eleanor; de Laguiche, Elisabeth; Vistisen, Dorte; Yin, Can; Adam, Atif |
|---|
| 組織名 | Department of Diabetes, Endocrinology and Metabolism, Kitasato University School;of Medicine, Sagamihara, Japan.;IQVIA Inc, London, UK.;Novo Nordisk A/S, Soborg, Denmark. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/42086460/ |
|---|
